The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger, E Buchdunger, BJ Druker - Blood, 2005 - ashpublications.org
Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …
studies were promising but the results of clinical trials by far exceeded expectations …
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation
M Miettinen, J Lasota - Applied immunohistochemistry & molecular …, 2005 - journals.lww.com
CD117 (KIT) is a type III receptor tyrosine kinase operating in cell signal transduction in
several cell types. Normally KIT is activated (phosphorylated) by binding of its ligand, the …
several cell types. Normally KIT is activated (phosphorylated) by binding of its ligand, the …
Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRα, PDGFRβ, and Met in large-cell neuroendocrine carcinoma of the lung
Purpose Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a relatively
uncommon, high-grade neuroendocrine tumor sharing several features with small-cell lung …
uncommon, high-grade neuroendocrine tumor sharing several features with small-cell lung …
Normal and oncogenic forms of the receptor tyrosine kinase kit
J Lennartsson, T Jelacic, D Linnekin, R Shivakrupa - Stem cells, 2005 - academic.oup.com
Kit is a receptor tyrosine kinase (RTK) that binds stem cell factor. This receptor ligand
combination is important for normal hematopoiesis, as well as pigmentation, gut function …
combination is important for normal hematopoiesis, as well as pigmentation, gut function …
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy
GS Warshamana-Greene, J Litz, E Buchdunger… - Clinical cancer …, 2005 - AACR
Purpose: Insulin-like growth factor-I (IGF-I) is a potent growth factor for small cell lung cancer
(SCLC) in both the autocrine and endocrine context. It also inhibits chemotherapy-induced …
(SCLC) in both the autocrine and endocrine context. It also inhibits chemotherapy-induced …
[HTML][HTML] A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study
GK Dy, AA Miller, SJ Mandrekar, MC Aubry… - Annals of oncology, 2005 - Elsevier
Background: The aim of the present study was to evaluate the clinical activity of imatinib
mesylate in patients with recurrent and refractory c-kit-expressing small-cell lung cancer …
mesylate in patients with recurrent and refractory c-kit-expressing small-cell lung cancer …
ZD6474 Suppresses Oncogenic RET Isoforms in a Drosophila Model for Type 2 Multiple Endocrine Neoplasia Syndromes and Papillary Thyroid Carcinoma
Patients with hereditary medullary thyroid carcinoma (MTC) associated with multiple
endocrine neoplasia (MEN) types 2A and 2B and familial MTC (FMTC) have mutations in the …
endocrine neoplasia (MEN) types 2A and 2B and familial MTC (FMTC) have mutations in the …
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein: a phase II clinical trial
LM Krug, JP Crapanzano, CG Azzoli… - … Journal of the …, 2005 - Wiley Online Library
BACKGROUND Imatinib inhibits the c‐kit tyrosine kinase, which, accounts for its activity in
gastrointestinal stromal tumors. The presence of c‐kit protein expression in small cell lung …
gastrointestinal stromal tumors. The presence of c‐kit protein expression in small cell lung …
Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines
S Matsumoto, S Kimura, H Segawa, J Kuroda, T Yuasa… - Lung Cancer, 2005 - Elsevier
Small cell lung cancer (SCLC) is one of the most aggressive types of cancers because of its
early development of regional and distant metastases. Novel and more effective therapeutic …
early development of regional and distant metastases. Novel and more effective therapeutic …
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung …
J Tsurutani, KA West, J Sayyah, JJ Gills, PA Dennis - Cancer research, 2005 - AACR
The fact that small cell lung cancer (SCLC) is commonly incurable despite being initially
responsive to chemotherapy, combined with disappointing results from a recent SCLC …
responsive to chemotherapy, combined with disappointing results from a recent SCLC …